WDR5 is required for DUX4 expression and its pathological effects in FSHD muscular dystrophy
Nucleic Acids Research · 2023
DOI: 10.1093/nar/gkad230 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, 2023. Verfasst von Emanuele Mocciaro und 10 weiteren Autor:innen. Beteiligte Einrichtung: Gene Expression and Muscular Dystrophy Unit, Division of Genetics and Cell Biology, IRCCS San Raffaele Scientific Institute, Milano, Italy. Hauptthemen laut MEDLINE: Muscular Dystrophy, Facioscapulohumeral. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Italian Ministry of Health, European Joint Programme on Rare Diseases.
Abstract (Originalsprache)
Facioscapulohumeral muscular dystrophy (FSHD) is one of the most prevalent neuromuscular disorders. The disease is linked to copy number reduction and/or epigenetic alterations of the D4Z4 macrosatellite on chromosome 4q35 and associated with aberrant gain of expression of the transcription factor DUX4, which triggers a pro-apoptotic transcriptional program leading to muscle wasting. As today, no cure or therapeutic option is available to FSHD patients. Given its centrality in FSHD, blocking DUX4 expression with small molecule drugs is an attractive option. We previously showed that the long non protein-coding RNA DBE-T is required for aberrant DUX4 expression in FSHD. Using affinity purification followed by proteomics, here we identified the chromatin remodeling protein WDR5 as a novel DBE-T interactor and a key player required for the biological activity of the lncRNA. We found that WDR5 is required for the expression of DUX4 and its targets in primary FSHD muscle cells. Moreover, targeting WDR5 rescues both cell viability and myogenic differentiation of FSHD patient cells. Notably, comparable results were obtained by pharmacological inhibition of WDR5. Importantly, WDR5 targeting was safe to healthy donor muscle cells. Our results support a pivotal role of WDR5 in the activation of DUX4 expression identifying a druggable target for an innovative therapeutic approach for FSHD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Gene Expression and Muscular Dystrophy Unit, Division of Genetics and Cell Biology, IRCCS San Raffaele Scientific Institute, Milano, Italy.
- Division of Molecular Biology, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-University (LMU), Munich, Germany.
- ProMeFa, Proteomics and Metabolomics Facility, IRCCS San Raffaele Scientific Institute, Milano, Italy.
ORCID-Profile: Filippo M Cernilogar, Gunnar Schotta, Davide Gabellini
Förderung
- NCI NIH HHS
- Italian Ministry of Health
- European Joint Programme on Rare Diseases
- Italian Association for Cancer Research
- National Institutes of Health—National Cancer Institute
- FSHD Society
- Marie Skłodowska-Curie
- Vita-Salute San Raffaele University
Zitieren
APA
Mocciaro, E., Giambruno, R., Micheloni, S., Cernilogar, F. M., Andolfo, A., Consonni, C., Pannese, M., Ferri, G., Runfola, V., Schotta, G., & Gabellini, D. (2023). WDR5 is required for DUX4 expression and its pathological effects in FSHD muscular dystrophy. Nucleic Acids Research. https://doi.org/10.1093/nar/gkad230
Vancouver
Mocciaro E, Giambruno R, Micheloni S, Cernilogar FM, Andolfo A, Consonni C, et al. WDR5 is required for DUX4 expression and its pathological effects in FSHD muscular dystrophy. Nucleic Acids Research. 2023. doi:10.1093/nar/gkad230
BibTeX
@article{Mocciaro2023,
author = {Mocciaro, Emanuele and Giambruno, Roberto and Micheloni, Stefano and Cernilogar, Filippo M and Andolfo, Annapaola and Consonni, Cristina and Pannese, Maria and Ferri, Giulia and Runfola, Valeria and Schotta, Gunnar and Gabellini, Davide},
title = {WDR5 is required for DUX4 expression and its pathological effects in FSHD muscular dystrophy},
journal = {Nucleic Acids Research},
year = {2023},
doi = {10.1093/nar/gkad230}
}
EUVIMED